Thomas Thiele
YOU?
Author Swipe
View article: Donation initiators: Shifting the focus from outcome to first‐time engagement ‐ An interview study
Donation initiators: Shifting the focus from outcome to first‐time engagement ‐ An interview study Open
Background A stable whole‐blood supply is vital to healthcare and relies on the successful recruitment and retention of donors, with first‐time donors playing a key role in replacing those who lapse over time. The initial donation attempt …
View article: Platelet-activating histone/antihistone IgG complexes in anti-PF4–negative thrombosis and thrombocytopenia syndrome
Platelet-activating histone/antihistone IgG complexes in anti-PF4–negative thrombosis and thrombocytopenia syndrome Open
Thrombosis and thrombocytopenia syndromes (TTS) describe immune-mediated thrombotic adverse reactions after vaccination against COVID-19. Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a well-known subentity of TTS, caused by…
View article: Patient Plasma Management
Patient Plasma Management Open
View article: Streptococcus pyogenes Activates Human Platelets via Streptolysin S-Mediated Calcium Ion Influx
Streptococcus pyogenes Activates Human Platelets via Streptolysin S-Mediated Calcium Ion Influx Open
Introduction: Streptococcus pyogenes (group A streptococcus, GAS) is an exclusively human pathogen. It causes a wide spectrum of diseases, ranging from mild infections such as pharyngitis to severe life-threatening conditions such as strep…
View article: Anti-Platelet factor 4 immunothrombosis—not just heparin and vaccine triggers
Anti-Platelet factor 4 immunothrombosis—not just heparin and vaccine triggers Open
Derailments at the tightly regulated interface of blood coagulation and innate inflammatory immune responses can lead to pathologic immunothrombosis. A special subset of immunothrombosis is caused by antibodies against platelet-factor 4 (P…
View article: Recombinant Anti-PF4 Antibodies Derived from Patients with Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Facilitate Research and Laboratory Diagnosis of VITT
Recombinant Anti-PF4 Antibodies Derived from Patients with Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Facilitate Research and Laboratory Diagnosis of VITT Open
Background/Objectives: Adenoviral vector-based vaccines against COVID-19 rarely cause vaccine-induced immune thrombocytopenia and thrombosis (VITT), a severe adverse reaction caused by IgG antibodies against platelet factor 4 (PF4). To stu…
View article: Enhanced platelet sensitization is accompanied by increased expression of the transporter MRP4 and elevated plasma S1P levels in mild COVID-19 convalescents
Enhanced platelet sensitization is accompanied by increased expression of the transporter MRP4 and elevated plasma S1P levels in mild COVID-19 convalescents Open
Viral infections can lead to platelet activation and hemostatic complications. However, the extent to which platelet reactivity remains altered after convalescence, contributing to long-term health impairments as observed after COVID-19 is…
View article: Cranioplasty after Decompressive Craniectomy (DC) in a Patient with Intracerebral Hemorrhage after SARS-CoV-2 Vaccination-Related Vaccine-Induced Thrombotic Thrombocytopenia (VITT)—Proposal of a Management Protocol for This Rare Pathological Condition
Cranioplasty after Decompressive Craniectomy (DC) in a Patient with Intracerebral Hemorrhage after SARS-CoV-2 Vaccination-Related Vaccine-Induced Thrombotic Thrombocytopenia (VITT)—Proposal of a Management Protocol for This Rare Pathological Condition Open
The COVID-19 (coronavirus disease) pandemic had a severe impact on public health worldwide. A rare but serious complication after administration of adenoviral vaccines against SARS-CoV-2 (AstraZeneca–Oxford and Johnson & Johnson) is vaccin…
View article: Continuation of chronic antiplatelet therapy is not associated with increased need for transfusions: a cohort study in critically ill septic patients
Continuation of chronic antiplatelet therapy is not associated with increased need for transfusions: a cohort study in critically ill septic patients Open
Background The decision to maintain or halt antiplatelet medication in septic patients admitted to intensive care units presents a clinical dilemma. This is due to the necessity to balance the benefits of preventing thromboembolic incident…
View article: Purified Granulocyte Concentrates from Buffy Coats with Extended Storage Time
Purified Granulocyte Concentrates from Buffy Coats with Extended Storage Time Open
Background: Granulocyte concentrates (GCs) are usually prepared by single-donor apheresis after G-CSF pretreatment and have to be transfused within 24 h after cell collection because of the rapid decrease in pH and cell survi…
View article: An anti-PF4 antibody-related disorder with cerebral venous sinus thrombosis and thrombocytopenia initially presenting as intracranial hemorrhage
An anti-PF4 antibody-related disorder with cerebral venous sinus thrombosis and thrombocytopenia initially presenting as intracranial hemorrhage Open
View article: A Call to Reinvent Platelet Products
A Call to Reinvent Platelet Products Open
Platelet storage is a well-preserved routine procedure in blood banking. Platelet concentrates (PCs) are stored under continuous agitation in gas-permeable bags to allow sufficient gas exchange between platelets and the ambient air. The st…
View article: Pro-inflammatory sensitization of platelets after a mild course of COVID-19 infection
Pro-inflammatory sensitization of platelets after a mild course of COVID-19 infection Open
Background Coronavirus disease-2019 (COVID-19) is a viral respiratory illness caused by the severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) which can lead to an increased risk of thromboembolic events but also complicatio…
View article: Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure
Anti-PF4 immunothrombosis without proximate heparin or adenovirus vector vaccine exposure Open
Platelet-activating anti-platelet factor 4 (PF4)/heparin antibodies and anti-PF4 antibodies cause heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT), respectively. Diagnostic and treatm…
View article: PB1338 Thrombotic Thrombocytopenia Syndrome after vaccination against COVID-19 Associated with Antiplatelet Antibodies
PB1338 Thrombotic Thrombocytopenia Syndrome after vaccination against COVID-19 Associated with Antiplatelet Antibodies Open
View article: PB0891 Impact of Enhanced Platelet Turnover on Platelet Reactivity in Healthy Humans
PB0891 Impact of Enhanced Platelet Turnover on Platelet Reactivity in Healthy Humans Open
Aims: We report scale-up synthesis and characterization of a short nonfibrillar recombinant protein and demonstrate that important functional properties of fibrillar/native collagen in primary haemostasis are well mimicked.Methods: The bio…
View article: Laboratory and demographic predictors of functional assay positive status in suspected heparin-induced thrombocytopenia: A multicenter retrospective cohort study
Laboratory and demographic predictors of functional assay positive status in suspected heparin-induced thrombocytopenia: A multicenter retrospective cohort study Open
View article: Heparin- and Vaccine-Independent Anti-Platelet Factor 4 Immunothrombosis
Heparin- and Vaccine-Independent Anti-Platelet Factor 4 Immunothrombosis Open
View article: One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients
One-year follow-up of the CAPSID randomized trial for high-dose convalescent plasma in severe COVID-19 patients Open
BACKGROUNDResults of many randomized trials on COVID-19 convalescent plasma (CCP) have been reported, but information on long-term outcome after CCP treatment is limited. The objectives of this extended observation of the randomized CAPSID…
View article: Quantitative interpretation of PF4/heparin‐EIA optical densities in predicting platelet‐activating VITT antibodies
Quantitative interpretation of PF4/heparin‐EIA optical densities in predicting platelet‐activating VITT antibodies Open
View article: In mouse chronic pancreatitis CD25+FOXP3+ regulatory T cells control pancreatic fibrosis by suppression of the type 2 immune response
In mouse chronic pancreatitis CD25+FOXP3+ regulatory T cells control pancreatic fibrosis by suppression of the type 2 immune response Open
View article: SARS-CoV-2 Infection in Patients with a History of VITT
SARS-CoV-2 Infection in Patients with a History of VITT Open
View article: GPVI expression is linked to platelet size, age, and reactivity
GPVI expression is linked to platelet size, age, and reactivity Open
Platelets within one individual display heterogeneity in reactivity, size, age, and expression of surface receptors. To investigate the combined intraindividual contribution of platelet size, platelet age, and receptor expression levels on…
View article: Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia
Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia Open
Heparin, a widely used anticoagulant, carries the risk of an antibody-mediated adverse drug reaction, heparin-induced thrombocytopenia (HIT). A subset of heparin-treated patients produces detectable levels of antibodies against complexes o…
View article: Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway
Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway Open
Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare but highly morbid complication after adenoviral vector-based SARS-CoV-2 vaccination. The pre-VITT syndrome is defined as vaccine-induced immune thrombocytopenia without th…
View article: Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration
Thrombocytopenia and splenic platelet-directed immune responses after IV ChAdOx1 nCov-19 administration Open
Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are based on a range of novel platforms, with adenovirus-based approaches (like ChAdOx1 nCov-19) being one of them. Recently, a novel complication of SARS-CoV-2–…
View article: The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies
The deglycosylated form of 1E12 inhibits platelet activation and prothrombotic effects induced by VITT antibodies Open
In order to improve the safety of COVID-19 vaccines, there is an urgent need to unravel the pathogenesis of vaccineinduced immune thrombotic thrombocytopenia (VITT), a severe complication of recombinant adenoviral vector vaccines used to p…
View article: <i>ABO</i> O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia
<i>ABO</i> O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia Open
Heparin-induced thrombocytopenia (HIT) is an unpredictable, potentially catastrophic adverse effect resulting from an immune response to platelet factor 4 (PF4)/heparin complexes. We performed a genome-wide association study (GWAS) with po…
View article: Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT)
Pathogenesis of vaccine-induced immune thrombotic thrombocytopenia (VITT) Open
View article: Platelet size as a mirror for the immune response after SARS‐CoV‐2 vaccination
Platelet size as a mirror for the immune response after SARS‐CoV‐2 vaccination Open